Alliance for Clinical Trials in Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1156
- Registration Number
- NCT06671912
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1040
- Registration Number
- NCT06661720
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1100
- Registration Number
- NCT06632327
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Conditions
- Interventions
- Other: Genetic testingDrug: Valemetostat TosylateProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Bone scanProcedure: FDG-Positron Emission TomographyProcedure: PSMA PET ScanProcedure: Biospecimen CollectionDrug: CarboplatinDrug: CabazitaxelDrug: Abiraterone AcetateDrug: EnzalutamideDrug: Lutetium Lu 177 Vipivotide Tetraxetan
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT06632977
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT06232044
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 100
- Registration Number
- NCT06115499
- Locations
- 🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Saint Francis Medical Center, Cape Girardeau, Missouri, United States
🇺🇸Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- Drug: ZanubrutinibBiological: RituximabOther: Patient ObservationProcedure: Bone Marrow BiopsyOther: Fludeoxyglucose F-18Procedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: ColonoscopyProcedure: EsophagogastroduodenoscopyProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 421
- Registration Number
- NCT05976763
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Mercy Hospital Springfield, Springfield, Missouri, United States
🇺🇸Kalispell Regional Medical Center, Kalispell, Montana, United States
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1295
- Registration Number
- NCT05812807
- Locations
- 🇺🇸
Henry Ford Health Providence Southfield Hospital, Southfield, Michigan, United States
🇺🇸Henry Ford Health Providence Novi Hospital, Novi, Michigan, United States
🇺🇸NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 98
- Registration Number
- NCT05751668
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Morton Plant Hospital, Clearwater, Florida, United States
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 394
- Registration Number
- NCT05710406
- Locations
- 🇺🇸
The Queen's Medical Center - West Oahu, 'Ewa Beach, Hawaii, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Rush-Copley Healthcare Center, Yorkville, Illinois, United States